samedan logo

 
 
spacer
home > ict > winter 2019 > the balanced approach to optimising clinical trial design and execution
PUBLICATIONS
International Clinical Trials

The Balanced Approach to Optimising Clinical Trial Design and Execution

According to internal Phase 2 termination analysis, as many as 17% of clinical trials fail to answer the questions their sponsors had aimed to address (1). These failed trials end up wasting significant time, money, and resources, effectively ending with a whimper instead of a bang. Moreover, such failures are especially upsetting to patient communities, who must wait longer for new treatments.

In many cases, sponsors conduct dozens of trials at once without comprehensive data-led design and planning. All too often, sponsors activate hundreds of sites for a single trial without thoroughly analysing investigator site performance data. Even when a trial results in regulatory approval, it may have been dogged by a lack of operational excellence.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Gen Li PhD is founder and President of Phesi and is passionate about improving patients’ lives. Prior to founding Phesi in 2007, Gen was Head of Productivity at Pfizer in clinical development, following Pfizer’s acquisition of Pharmacia where he delivered the first implementation of clinical development productivity measurement. At Pharmacia/Pfizer, Gen significantly contributed to the Centre for Medicines Research international database for pharmaceutical R&D performance. Previously, he led the creation of the first computer-automated resource management system at Bristol-Myers Squibb. He earned his PhD in biochemistry from Beijing University, China, and an MBA from the Johnson Graduate School of Management at Cornell University, US.

Paul Chew MD is a board-certified cardiologist and internist and Chief Medical Officer at Phesi. He recently served as CMO at Silicon Valley-based Omada Health. Previously, Paul held various positions at Sanofi and Bristol- Myers Squibb, including Senior Vice President, Global Chief Medical Officer, and US R&D Head. He is currently on the Board of Trustees for the US Pharmacopoeial Convention. Paul spent 22 years at Johns Hopkins University, US, where he received his undergraduate and medical education, served his Osler medical residency, was a member of the interventional cardiology faculty, and held joint faculty appointments in radiology and cardiology.

Jonathan Peachey is Chief Operations Officer at Phesi with a background in business and IT transformation across pharma R&D for the past 25 years. Jonathan came to Phesi after serving as a Board Director at Kinapse, where he transformed the advisory and outsourcing delivery model for life sciences companies. Previously, Jonathan delivered business transformation for IBM’s EU pharma R&D consulting practice. He also led development projects at GlaxoSmithKline, Bristol-Myers Squibb, and Pfizer. Jonathan’s demonstrated capabilities span strategy, business and IT management, performance improvement and solution design, through to implementation. He holds a first class honours degree and an Advanced Strategy diploma from Said Business School, Oxford University, UK.


spacer
Gen Li PhD
spacer
spacer
spacer
Paul Chew MD
spacer
spacer
spacer
Jonathan Peachey
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Huge boom in Korean Pharma reported at CPhI Korea

Amsterdam, 19th September 2019: The recently-closed CPhI Korea – co-organised by Informa Markets and the Korea Pharmaceutical Traders Association (KPTA) – has seen a surge in growth across domestic and international pharma companies, as well as a sizable rise in overall attendees. As reported earlier this year in the provisional findings of the CPhI Pharma Index[1], Korea has seen a rapid growth in its international reputation (seeing its ‘overall competitiveness’ rise 14% in the last two years), which is now translating into a sizable growth in the market and at the event.
More info >>

White Papers

High Containment FIBCs Offer a Safe and Cost Effective Alternative to their Rigid Counterparts

ILC Dover

As the need for powder containment and manufacturing in accordance with cGMP standards has grown over the years, companies have sought new alternatives to rigid IBCs. Recently high containment Flexible Intermediate Bulk Containers (FIBCs) have emerged which offer an alternative that provides both powder containment and the benefits of shipping with flexibles.
More info >>

 
Industry Events

ESMO Targeted Anticancer Therapies Congress 2020

2-4 March 2020, Paris, France

A unique and international mix of experts, researchers and decision makers both from academia and industry across the globe, will convene in Paris for a three-day Congress aiming at exchanging knowledge, experience and research innovations in cancer. TAT 2020 will focus, among others, on novel strategies in immuno-oncology, personalised medicine and molecular tumour boards, preclinical studies to identify effective combination therapies, use of microbiome, tumour agnostic trials, ADC technology, oncolytics, multispecific biological constructs and targeting cytokines. Participating in TAT 2020 will offer you the possibility to take part in interdisciplinary discussions inspiring new ideas and new collaborations.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement